747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes TrialRichard E. Pratley, VLADO PERKOVIC, Jack Lawson et al.|Diabetes|2022Cited by 2
875-P: Baseline Characteristics for FINE-ONE—A Randomized Phase III Trial Assessing Finerenone in People with T1D and CKDHiddo J.L. Heerspink, Andreas L. Birkenfeld, David Cherney et al.|Diabetes|2025Cited by 0